I’m really happy to see this article—I mentioned it to givewell a while ago but they weren’t interested. For me this hits what I see as the moral priority more than a lot of the other projects and options on the go.
Simple, complex and neuropathic pains respond differently to different anaelgasics. Opioids v effective for simple pain over the short term, e.g. surgeries, broken bones etc. Neuropathic and complex pain don’t have good equivalents for pain relief and patients are stuck with cannabinoids, anti-epileptics and anti-depressants (or, ketamine, ironically, if it wasn’t so restricted in the developed world for its noted impact on organ function).
Not a reason not to back access to opioids in the developing world.
Least well explored part IMO is the impact of pain control on the nature of medicine and doctor-patient interaction etc. because the west may have fallen into a trap that it may be a shame to hasten in the developing world.
Great to hear that it’s been suggested. By the looks of it, it may be an area better suited to an Open Philanthropy Project-style approach, being primarily a question of policy and having a sparser evidence base and impact definition difficulties. I styled my analysis around OPP’s approach (with some obvious shortcomings on my part).
I could have done better in the analysis to distinguish between the various types of pain. As you say, they are not trivial distinctions, especially when it comes to treatment with opioids.
I’d be interested to hear your take on the impact of pain control on the nature of medicine and the doctor-patient dynamic. What trends are you concerned about hastening exactly?
The shift from patient as recipient of medicine from clinician with authority (old style developed world and much of e.g. Africa) to patient as consumer. There are good and bad things with this transition. Pain, pain control and patient perceptions are just under-studied as a nexus. Not a reason not to go ahead, just my biggest worry with this stuff. (I personally don’t think risk of death / side effects are much of a worry at all when we’re talking about opioid availability in inpatient settings).
I’m concerned in almost the opposite direction- that having the doctor as gatekeeper to something the patient legitimately needs, with the threat of taking it away if the patient doesn’t look sick enough, corrupts the doctor-patient relationship and the healing process.
I’m really happy to see this article—I mentioned it to givewell a while ago but they weren’t interested. For me this hits what I see as the moral priority more than a lot of the other projects and options on the go.
Simple, complex and neuropathic pains respond differently to different anaelgasics. Opioids v effective for simple pain over the short term, e.g. surgeries, broken bones etc. Neuropathic and complex pain don’t have good equivalents for pain relief and patients are stuck with cannabinoids, anti-epileptics and anti-depressants (or, ketamine, ironically, if it wasn’t so restricted in the developed world for its noted impact on organ function).
Not a reason not to back access to opioids in the developing world.
Least well explored part IMO is the impact of pain control on the nature of medicine and doctor-patient interaction etc. because the west may have fallen into a trap that it may be a shame to hasten in the developing world.
Hi Tom,
Great to hear that it’s been suggested. By the looks of it, it may be an area better suited to an Open Philanthropy Project-style approach, being primarily a question of policy and having a sparser evidence base and impact definition difficulties. I styled my analysis around OPP’s approach (with some obvious shortcomings on my part).
I could have done better in the analysis to distinguish between the various types of pain. As you say, they are not trivial distinctions, especially when it comes to treatment with opioids.
I’d be interested to hear your take on the impact of pain control on the nature of medicine and the doctor-patient dynamic. What trends are you concerned about hastening exactly?
The shift from patient as recipient of medicine from clinician with authority (old style developed world and much of e.g. Africa) to patient as consumer. There are good and bad things with this transition. Pain, pain control and patient perceptions are just under-studied as a nexus. Not a reason not to go ahead, just my biggest worry with this stuff. (I personally don’t think risk of death / side effects are much of a worry at all when we’re talking about opioid availability in inpatient settings).
I’m concerned in almost the opposite direction- that having the doctor as gatekeeper to something the patient legitimately needs, with the threat of taking it away if the patient doesn’t look sick enough, corrupts the doctor-patient relationship and the healing process.